SCHEMBL13633894

SCHEMBL13633894

Cc1nc(-c2cc3ccccc3s2)oc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.55
S1PR1 P21453 1/20 0.45
APP P05067 2/20 0.42
CYP2A6 P11509 3/20 0.39
ADRB2 P07550 1/20 0.39
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
ASIC3 Q9UHC3 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
CYP19A1 P11511 1/20 0.38
CA1 P00915 2/20 0.38
CA9 Q16790 2/20 0.38
CA2 P00918 1/20 0.38
NQO1 P15559 1/20 0.38
NQO2 P16083 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633788 0.82 IKBKB (0.47) IKBKBS1PR1APPCYP2A6ADRB2
SCHEMBL5761525 0.81 IKBKB (0.46) IKBKBS1PR1APPCYP2A6ADRB2
SCHEMBL4885386 0.79 PPARG (0.49) IKBKBS1PR1APPCYP2A6ADRB2
SCHEMBL19961702 0.74 IKBKB (0.51) IKBKBAPP
SCHEMBL29742225 0.74 IKBKB (0.51) IKBKBAPP
SCHEMBL13633783 0.72 PPARG (0.43) CYP2A6HSD17B1HSD17B2PPARGPPARA
SCHEMBL29732980 0.72 APP (0.63) APPCYP2A6ADRB2HSD17B1HSD17B2
SCHEMBL845603 0.72 APP (0.63) APPCYP2A6ADRB2HSD17B1HSD17B2
SCHEMBL13633786 0.72 ALDH1A1 (0.46) PPARGPPARA
SCHEMBL12606836 0.70 PSMB8 (0.51) IKBKBS1PR1APPCYP2A6ASIC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 IKBKB 585/4885S1PR1 2764/4885APP 504/4885
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 IKBKB 1392/4885S1PR1 3565/4885APP 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.